Alzheimer’s Drug Discovery Foundation – Accelerating Drug Discovery for Frontotemporal Degeneration| Research Funding
Event details
| Date | 20.05.2022 |
| Category | Call for proposal |
Aim: There are currently no FDA approved disease-modifying treatments available for frontotemporal dementia (FTD), and symptomatic treatments only provide limited benefit for patients. Recent scientific advances have provided an increased understanding of pathogenic mechanisms underlying FTD and are driving the development of potential disease-modifying therapies. The Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate this progress by supporting innovative small molecule and biologic (antibodies, oligonucleotides, peptides, gene therapy etc.) drug development programs for FTD through this request for proposals (RFP).
The funding priorities for this RFP are:
Funding: max. $150,000
Duration: 1 year, with potential for follow-up funding
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step, and are submitted through the ADFF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Deadlines: 20-May-2022 (letter of intent)
30-July-2022 (full proposal, by invitation)
Further information
The funding priorities for this RFP are:
- Lead optimization of novel disease-modifying compounds, including medicinal chemistry refinement and in vitro ADME.
- In vivo testing of novel lead compounds, biologics, vaccines, or repurposed drug candidates in relevant animal models for pharmacokinetics, dose-range finding, target engagement, in vivo efficacy, and/or preliminary rodent tolerability studies.
Funding: max. $150,000
Duration: 1 year, with potential for follow-up funding
Eligibility: Funding is open to researchers and clinicians worldwide at academic medical centers and universities or nonprofits. Industry partnerships are encouraged.
How to Apply: Applications are reviewed in a two-step process: Letters of Intent (LOI) are the first step, and are submitted through the ADFF Funding Portal. ADDF’s science team will evaluate LOIs to determine whether the proposed project is consistent with the ADDF's mission and funding priorities. LOI decisions will be sent within three weeks of submission. Step 2 is an invited full proposal, which should include a detailed project narrative, budget and justification, and biographical information. When formulating the budget, note that the following costs are not covered: Indirect costs/Overhead, Publication costs, Equipment, and Travel.
Deadlines: 20-May-2022 (letter of intent)
30-July-2022 (full proposal, by invitation)
Further information
- More information about the program is available here
- Detailed application instructions are here
- The application portal can be found here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free